Terms: = Skin cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
56 results:
1. The role of thymic stromal lymphopoietin in cutaneous disorders.
Jafari AJ; Rivera M; Hebert AA
Arch Dermatol Res; 2024 Apr; 316(5):123. PubMed ID: 38630260
[TBL] [Abstract] [Full Text] [Related]
2. Lymphadenectomy After Melanoma-A National Analysis of Recurrence Rates and Risk of Lymphedema.
Shen C; Shah JK; Cevallos P; Nazerali R; Rosen JM
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S284-S292. PubMed ID: 38556691
[TBL] [Abstract] [Full Text] [Related]
3. Effects of extracellular vesicles from adipose-derived stem cells on human keloid fibroblasts via the SOCS1/jak2/STAT3 pathway.
Ruan H; Wang J; Shi H; Luan W
J Cosmet Dermatol; 2024 Apr; 23(4):1404-1416. PubMed ID: 38288516
[TBL] [Abstract] [Full Text] [Related]
4. Radix Tetrastigma Hemsleyani Flavone represses cutaneous squamous cell carcinoma via Janus kinase/signal transducer and activator of transcription 3 pathway inactivation.
Peng J; Luo X; Wang T; Yue C; Duan M; Wu C
Cytokine; 2024 Mar; 175():156480. PubMed ID: 38232644
[TBL] [Abstract] [Full Text] [Related]
5. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract] [Full Text] [Related]
6. Acute graft-versus-host disease.
Malard F; Holler E; Sandmaier BM; Huang H; Mohty M
Nat Rev Dis Primers; 2023 Jun; 9(1):27. PubMed ID: 37291149
[TBL] [Abstract] [Full Text] [Related]
7. MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of jak2.
Markovits E; Harush O; Baruch EN; Shulman ED; Debby A; Itzhaki O; Anafi L; Danilevsky A; Shomron N; Ben-Betzalel G; Asher N; Shapira-Frommer R; Schachter J; Barshack I; Geiger T; Elkon R; Besser MJ; Markel G
Cancer Immunol Res; 2023 Jul; 11(7):909-924. PubMed ID: 37074069
[TBL] [Abstract] [Full Text] [Related]
8. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Grauslund JH; Holmström MO; Martinenaite E; Lisle TL; Glöckner HJ; El Fassi D; Klausen U; Mortensen REJ; Jørgensen N; Kjær L; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1117466. PubMed ID: 36911725
[TBL] [Abstract] [Full Text] [Related]
9. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract] [Full Text] [Related]
10. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T; Katoh N; Simpson EL; de Bruin-Weller M; Thaçi D; Torrelo A; Sontag A; Grond S; Issa M; Lu X; Cardillo T; Holzwarth K; Thyssen JP
J Dermatolog Treat; 2023 Dec; 34(1):2161812. PubMed ID: 36546346
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic targets and signaling mechanisms of dasatinib activity against radiation skin ulcer.
Su W; Chen X; Zhang W; Li D; Chen X; Yu D
Front Public Health; 2022; 10():1031038. PubMed ID: 36530656
[TBL] [Abstract] [Full Text] [Related]
12. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
13. PCM1::jak2 fusion associates with an atypical form of mycosis fungoides.
Rodriguez-Sevilla JJ; Salido M; Rodriguez-Rivera M; Sanchez-Gonzalez B; Gallardo F; Pujol RM; Colomo L
Virchows Arch; 2022 Dec; 481(6):967-973. PubMed ID: 35786767
[TBL] [Abstract] [Full Text] [Related]
14. Hernandezine Regulates Proliferation and Autophagy-Induced Apoptosis in Melanoma Cells.
Wang X; Li X; Xia Y; Wang D; Li X; Liu L; Zheng Q; Li D; Jiang Q
J Nat Prod; 2022 May; 85(5):1351-1362. PubMed ID: 35544345
[TBL] [Abstract] [Full Text] [Related]
15. ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting jak2.
Zhu M; Liu Y; Lei P; Shi X; Tang W; Huang X; Pan X; Wang C; Ma W
Curr Cancer Drug Targets; 2022; 22(4):328-339. PubMed ID: 35220934
[TBL] [Abstract] [Full Text] [Related]
16. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3.
Zhao K; Dai Q; Wu J; Wei Z; Duan Y; Chen B
Eur J Cancer; 2022 Apr; 165():58-70. PubMed ID: 35219024
[TBL] [Abstract] [Full Text] [Related]
17. A Case of Thrombotic Vasculopathy in the Setting of High-Dose Hydroxyurea Use.
Michalak J; Simman R; Oostra D
Wounds; 2021 Dec; 33(12):E79-E84. PubMed ID: 34882096
[TBL] [Abstract] [Full Text] [Related]
18. Kinase Inhibition as treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract] [Full Text] [Related]
19. Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.
Iwasaki T; Hayashi K; Matsushita M; Nonaka D; Kohashi K; Kuwamoto S; Umekita Y; Oda Y
Cancer Sci; 2022 Jan; 113(1):251-260. PubMed ID: 34724284
[TBL] [Abstract] [Full Text] [Related]
20. Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of jak2/STAT3 signaling pathway in human melanoma cells.
Raut PK; Lee HS; Joo SH; Chun KS
Food Chem Toxicol; 2021 Nov; 157():112604. PubMed ID: 34627931
[TBL] [Abstract] [Full Text] [Related]
[Next]
